RSLS Quote, Financials, Valuation and Earnings

Altimmune has a net margin of -68.98% compared to Reshape Lifesciences's net margin of -463600%. Reshape Lifesciences's return on equity of -187.93% beat Altimmune's return on equity of -61.21%.

Reshape Lifesciences has a consensus price target of --, signalling upside risk potential of 21671.75%. On the other hand Altimmune has an analysts' consensus of $22.38 which suggests that it could grow by 300.27%. Given that Reshape Lifesciences has higher upside potential than Altimmune, analysts believe Reshape Lifesciences is more attractive than Altimmune.

Reshape Lifesciences has a beta of 1.480, which suggesting that the stock is 48.008% more volatile than S&P 500. In comparison Altimmune has a beta of 1.131, suggesting its more volatile than the S&P 500 by 13.05%.

Reshape Lifesciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Altimmune offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Reshape Lifesciences pays -- of its earnings as a dividend. Altimmune pays out -- of its earnings as a dividend.

Reshape Lifesciences quarterly revenues are $2.3M, which are larger than Altimmune quarterly revenues of $5K. Reshape Lifesciences's net income of -$1.6M is higher than Altimmune's net income of -$23.2M. Notably, Reshape Lifesciences's price-to-earnings ratio is -- while Altimmune's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Reshape Lifesciences is 0.02x versus 19,847.49x for Altimmune. Usually stocks with elevated PS ratios are considered overvalued.

Endo has a net margin of -68.98% compared to Reshape Lifesciences's net margin of -54.58%. Reshape Lifesciences's return on equity of -187.93% beat Endo's return on equity of --.

Reshape Lifesciences has a consensus price target of --, signalling upside risk potential of 21671.75%. On the other hand Endo has an analysts' consensus of $40.00 which suggests that it could grow by 86.57%. Given that Reshape Lifesciences has higher upside potential than Endo, analysts believe Reshape Lifesciences is more attractive than Endo.

Reshape Lifesciences has a beta of 1.480, which suggesting that the stock is 48.008% more volatile than S&P 500. In comparison Endo has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Reshape Lifesciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Endo offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Reshape Lifesciences pays -- of its earnings as a dividend. Endo pays out -- of its earnings as a dividend.

Reshape Lifesciences quarterly revenues are $2.3M, which are smaller than Endo quarterly revenues of $426.5M. Reshape Lifesciences's net income of -$1.6M is higher than Endo's net income of -$232.8M. Notably, Reshape Lifesciences's price-to-earnings ratio is -- while Endo's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Reshape Lifesciences is 0.02x versus -- for Endo. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals has a net margin of -68.98% compared to Reshape Lifesciences's net margin of 26.7%. Reshape Lifesciences's return on equity of -187.93% beat Regeneron Pharmaceuticals's return on equity of 15.7%.

Reshape Lifesciences has a consensus price target of --, signalling upside risk potential of 21671.75%. On the other hand Regeneron Pharmaceuticals has an analysts' consensus of $796.67 which suggests that it could grow by 51.6%. Given that Reshape Lifesciences has higher upside potential than Regeneron Pharmaceuticals, analysts believe Reshape Lifesciences is more attractive than Regeneron Pharmaceuticals.

Reshape Lifesciences has a beta of 1.480, which suggesting that the stock is 48.008% more volatile than S&P 500. In comparison Regeneron Pharmaceuticals has a beta of 0.427, suggesting its less volatile than the S&P 500 by 57.331%.

Reshape Lifesciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals offers a yield of 0.17% to investors and pays a quarterly dividend of $0.88 per share. Reshape Lifesciences pays -- of its earnings as a dividend. Regeneron Pharmaceuticals pays out -- of its earnings as a dividend.

Reshape Lifesciences quarterly revenues are $2.3M, which are smaller than Regeneron Pharmaceuticals quarterly revenues of $3B. Reshape Lifesciences's net income of -$1.6M is lower than Regeneron Pharmaceuticals's net income of $808.7M. Notably, Reshape Lifesciences's price-to-earnings ratio is -- while Regeneron Pharmaceuticals's PE ratio is 13.44x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Reshape Lifesciences is 0.02x versus 4.28x for Regeneron Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Viking Therapeutics has a net margin of -68.98% compared to Reshape Lifesciences's net margin of --. Reshape Lifesciences's return on equity of -187.93% beat Viking Therapeutics's return on equity of --.

Reshape Lifesciences has a consensus price target of --, signalling upside risk potential of 21671.75%. On the other hand Viking Therapeutics has an analysts' consensus of $90.26 which suggests that it could grow by 227.63%. Given that Reshape Lifesciences has higher upside potential than Viking Therapeutics, analysts believe Reshape Lifesciences is more attractive than Viking Therapeutics.

Reshape Lifesciences has a beta of 1.480, which suggesting that the stock is 48.008% more volatile than S&P 500. In comparison Viking Therapeutics has a beta of 0.754, suggesting its less volatile than the S&P 500 by 24.558%.

Reshape Lifesciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Viking Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Reshape Lifesciences pays -- of its earnings as a dividend. Viking Therapeutics pays out -- of its earnings as a dividend.

Reshape Lifesciences quarterly revenues are $2.3M, which are larger than Viking Therapeutics quarterly revenues of --. Reshape Lifesciences's net income of -$1.6M is higher than Viking Therapeutics's net income of -$45.6M. Notably, Reshape Lifesciences's price-to-earnings ratio is -- while Viking Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Reshape Lifesciences is 0.02x versus -- for Viking Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.